Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
DOI:
https://doi.org/10.33393/grhta.2022.2383Abstract
In the article “Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy”, (1) which appeared in Volume 8, Issue 1 of Global & Regional Health Technology Assessment, the values appearing in Fig. 5 C and D, inadvertently repeated the values reported in Fig. 5 A and B. Affected data have been corrected in the article now appearing online. The authors apologize for any inconvenience caused to the readers by these changes, which do not affect the final results of the study.
The final version of this article is available online and includes a reference to this correction.
Downloads
References
Caporali R, Ravasio R, Raimondo P, Salaffi F. Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy. Glob Region Health Technol Assess. 2021;8:69-79. https://doi.org/10.33323/grhta.2021.2267 DOI: https://doi.org/10.33393/grhta.2021.2267
Published
How to Cite
License
Copyright (c) 2022 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2022-02-10
Published 2022-02-17
